Abstract
Adoptive immunotherapy of cancer involving activated cells of the immune system has been used on a extended basis in clinical oncology. Randomized studies showed that the combination of IL-2 with LAKs was most effective as compared with the IL-2 therapy alone. Despite the fact that the immunotherapy basic research is focused on melanoma, renal cancer, colorectal cancer and lymphomas, there are published data related to an effective use of IL-2/LAK-therapy in patients with other localizations. Adminstration of IL-2 and LAKs for effusion forms of cancer led to clinical effects in 88–94% of cases. A maximum cytoreducation of tumor is an additional way to enhance the efficacy of immunotherapy; it ensures the establishment of maximum correlation between tumor cells and killers. A combination of methods for activation of specific and non-specific immunity should be regarded as the most promising trend in the development of anti-tumor biotherapy. A promising approach in immunotherapy involves simultaneous treatment with LAKs and DCs that can stimulate both innate and adaptive anti-tumor immunity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Blymenberg AG, Kiselevski MV, Gorbunova VA et al. (2002) Immunotherapy IL-2/LAK for the treatment of platinum and taxman-resistant advanced. Int J Gynecol Cancer 12(5):OV070.
Boiardi A, Silvani A, Ruffini P et al. (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39(3):193–197.
Chikileva IO, Khalturina EO, Kiselevsky MV (2003) Current approaches and trends in immunotherapy and immuno-prophylactics of cancer. Mol Med 2:40–50.
Davydov MI, Normantovich VA, Polotsky BE et al. (1996) Adoptive immuno-lympho-chemotherapy of non-small cell lung cancer. Vestnik AMN 3:3–9.
Davydov MI, Normantovich VA, Kiselevsky MV et al. (2000) Adoptive immunotherapy in malignant effusions: clinical and laboratory study. Russian Oncol J 6:14–17.
Davydov MI, Normantovich VA (2003) New approaches to combined anti-cancer treatment. Moscow, Publisher Medicine:211–223.
Davydov MI, Aksel EM (2006) Statistics of cancer in Russia and CIS countries in 2004. Vtstnic RCCR 17(3 Suppl 1):1–132.
Goldfarb RH, Brunson KW (2002) Antimetastatic therapy. Biologic Therapy of Cancer Vincent T. DeVita Jr., Samuel Hellman, Ateven A. Rosenberg (eds) Moscow, Publisher Medicine:878–887.
Hishii M, Andrews D, Boyle LA et al. (1997) In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci 94(4):1378–1383.
Kimura H, Yamaguchi Y (1997) A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80(1):42–49.
Kiselevsky MV (2003) Adoptive immunotherapy in cancer. Vestnik RAMS 1:40–44.
Kjaergaard J, Marianne E, Agger R et al. (2000) Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals. Cancer Immunol Immunother 48(10):550–560.
Kobari M, Egawa S, Shibuya K et al. (2000) Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br J Surg 87(1):43–48.
Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA et al. (2000) Increased intensity lymphodepletion and adoptive immunotherapy – how far can we go? Nat Clin Pract Oncol 3(12):668–681.
Porgador A, Mandelboim O, Restifo NP, Strominger JL (1997) Natural killer cell lines kill autologous β2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 94(24):13140–13145.
Rosenberg SA (2002) Adoptive immunotherapy: clinical application. Biologic Therapy of Cancer Vincent T. DeVita Jr., Samuel Hellman, Steven A. Rosenberg (eds) Moscow, Publisher Medicine.
Savas B, Arslan G, Gelen T, Karpuzoglu G, Ozkaynak C (1999) Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Res 9(5C):4413–4420.
Semino C, Martini L, Queirolo P, et al. (1999) Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. Anticancer Res 19(6C):5645–5649.
Toh U, Yamana H, Sueyoshi S et al. (2000) Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 6(12):4663–4673.
Topalian SL (2002) Adoptive cell therapy: preclinical studies. Biologic Therapy of Cancer Vincent T. DeVita Jr., Samuel Hellman, Ateven A. Rosenberg (eds) Moscow, Publisher Medicine: 484–503.
Tresoldi M, Chies G (1994) Intrapleural administration of interleukine-2 and LAK cells in locally advanced non-small-cell lung cancer. Tumori 80(3):246–250.
Ueda Y, Sonoyama T, Itoi H et al. (2000) Locoregional adoptive immunotherapy using LAK cells and IL-2 against liver metastases from digestive tract cancer. Gan To Kagaku Ryoho 27(12):1962–1965.
Yamaguchi Y, Ohshita A, Kawabuchi Y et al.(2003) Adoptive immunotherapy of cancer using activated autologous lymphocytes – current status and new strategies. Hum Cell 16(4):183–189.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Shubina, I.Z., Demidov, L.V., Chikileva, I.O., Lebedinskaya, O.V., Kiselevsky, M.V. (2008). LAK immunotherapy in clinical studies. In: Kiselevsky, M.V. (eds) Atlas Effectors of Anti-Tumor Immunity. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6931-4_7
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6931-4_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6930-7
Online ISBN: 978-1-4020-6931-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)